KIORA PHARMACEUTICALS, INC. Current Foreign Tax Expense (Benefit)
KIORA PHARMACEUTICALS, INC. (KPRX) reported Current Foreign Tax Expense (Benefit) of -$14.78 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentForeignTaxExpenseBenefit · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. current foreign tax expense (benefit) for fiscal 2025 was -$14.78K, a 101.47% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. current foreign tax expense (benefit) for fiscal 2024 was $1.01M.
- KIORA PHARMACEUTICALS, INC. current foreign tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Current Foreign Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$14.78K 10-K · filed 2026-03-25 |
| 2024-12-31 | $1.01M 10-K · filed 2026-03-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |